SCHEMBL2363524

SCHEMBL2363524

FC(F)(F)Oc1cccc(OCC2CCNC2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.59
SLC6A2 P23975 6/20 0.59
SLC6A3 Q01959 3/20 0.59
KCNH2 Q12809 3/20 0.48
HTR3A P46098 2/20 0.48
KDM1A O60341 1/20 0.44
MAOB P27338 1/20 0.44
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
PIM1 P11309 2/20 0.44
HTR2C P28335 1/20 0.42
PRKCZ Q05513 1/20 0.42
FLT3 P36888 1/20 0.41
PIM3 Q86V86 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MAP2K1 Q02750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14312000 0.89 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL9923476 0.82 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL12075488 0.80 SLC6A2 (0.60) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL17277590 0.80 SLC6A2 (0.60) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL26668494 0.79 SLC6A2 (0.71) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL24176193 0.79 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL17277533 0.79 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL17277362 0.79 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL31071592 0.79 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3KCNH2HTR3A
SCHEMBL12062272 0.78 SLC6A2 (0.59) SLC6A4SLC6A2SLC6A3KCNH2HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105837565-A ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION 赛诺菲 2016-08-10 CN disclosed
CN-102803258-B Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use SAI NUOFEI (FR) 2016-04-20 CN disclosed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 SLC6A4 3841/4885SLC6A2 2876/4885SLC6A3 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.